Clinical Trial Update: Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19 [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of Dipeptidyl Peptidase-4 inhibitors (e.g., linagliptin) in diabetic patients with established COVID-19; study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronavirus Disease
• Diabetes Mellitus
• Type 2 Diabetes Mellitus

Drugs mentioned

• Linagliptin (linagliptin)

Snippet

Sponsor: Rabin Medical Center | Conditions: COVID 19, Coronavirus | Phase 3 | Status: TERMINATED